Drug Delivery Devices Market Size

Drug Delivery Devices Market size was over USD 301.94 billion in 2024 and is set to cross USD 603.34 billion by the end of 2037, growing at more than 5.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of drug delivery devices is estimated at USD 315.23 billion. The growth of the market can be attributed to the increasing worldwide incidence of chronic diseases, and the ongoing efforts to adopt the best vaccines. In accordance to the National Library of Medicine, cardiovascular disease, cancer, chronic lung disease, and diabetes account for one-third of all fatalities worldwide.

Furthermore, increased spending on healthcare improvement is one of the primary reasons driving the growth of the drug delivery devices market. The global spending on healthcare per person increased from USD 864.313 in 2008 to USD 1,110.841 in 2018, with the United States leading the way with a healthcare expenditure of USD 10, 623.85 per capita in 2018.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of drug delivery devices is estimated at USD 315.23 billion.

The drug delivery devices market size was over USD 301.94 billion in 2024 and is set to cross USD 603.34 billion by the end of 2037, growing at more than 5.6% CAGR during the forecast period i.e., between 2025-2037. The increasing need for targeted drug delivery to treat cancer will boost the market growth.

North America industry is likely to hold a majority of the share accounted to by 2037, owing to increased product releases and initiatives by leading industry participants.

The major players in the market include Antares Pharma, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited.

Drug Delivery Devices Market Size